Trial Profile
A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) + Electroporation With Pembrolizumab in Patients With Stage 3/4 Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tavokinogene telseplasmid (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-695; PISCES
- Sponsors OncoSec Medical
- 03 Apr 2023 Primary endpoint has not been met (Overall Response Rate (ORR)) , according to an OncoSec Medical media release.
- 03 Apr 2023 According to an OncoSec Medical media release, last patient started treatment in Dec 2020 and clinical database lock occurred in Oct 2022.
- 03 Apr 2023 Results presented in an OncoSec Medical media release.